The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel)
... for the treatment of multiple myeloma
Recent publication
Prof. DDr Klaus Podar, Senior Physician at the Division of Internal Medicine 2 at the University Hospital Krems and Head of the Division of Molecular Oncology and Haematology at Karl Landsteiner University, writes together with Irene Strassl, Senior Physician at the Department of Medical Oncology and Haematology at the Ordensklinikum Linz, about the current status and progress in the treatment of multiple myeloma. Cilta-cel, which is already being administered to heavily treated patients with multiple myeloma, is moving closer to becoming a standard therapeutic agent, as is Ide-cel. Both have shown promising results in clinical trials. The two experts summarise the approval process for these modern immunotherapeutics from the CAR-T cell family and provide an outlook on future developments. Their expert opinion has been published in the journal "Expert Opinion on Drug Discovery".
Strassl I, Podar K. The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma. Expert Opinion on Drug Discovery. 2024 Feb 18;1-15. Epub 2024 Feb 18. doi: 10.1080/17460441.2024.2319672
OA Univ.-Prof. Mag. DDr. Klaus Podar
Head of
Division of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)
